News

Beijing – September 21, 2026 -- T-MAXIMUM Pharmaceutical reported that two of three evaluable patients with refractory brain metastases from lung cancer achieved partial responses with roughly 80% tumor shrinkage after treatment with its allogeneic B7-H3-targeted CAR-T therapy, MT027, according to early data presented at the IASLC World Conference on Lung Cancer (WCLC 2026) in Seoul.

Two of three evaluable patients hit 80% tumor shrinkage in dose-escalation trial

In the prospective, investigator-initiated trial (ChiCTR2500107346), five patients with heavily pretreated, guideline-exhausted brain metastases completed treatment. Of the three with measurable disease, two achieved partial responses and one achieved stable disease. As of the company's September 2026 follow-up, the two responders have survived more than 11 and 13 months, respectively, since their first MT027 dose, and all three evaluable patients remain alive.

CHARLESTON, S.C. – – September 21, 2026 -- VIO Med Spa has signed a three-unit development agreement to enter South Carolina for the first time, with the first Charleston-area location targeted to open in 2027. Site selection is currently underway.

Former CVS Health Executive Leads Local Development

Ted Loya, who spent more than 23 years at CVS Health in its pharmacy benefits business working with national employers, will spearhead the brand's build-out across the Charleston area. New to franchising and medical aesthetics, Loya cited VIO's established infrastructure, financial backing, and existing East Coast footprint in North Carolina and Georgia as deciding factors in bringing the brand to South Carolina.

Deal Extends Brand's East Coast Footprint

Ryan Rao, Chief Development Officer at VIO Med Spa, said the Charleston entry strengthens the company's presence in the Southeast and supports further expansion along the East Coast.

Las Vegas – September 21, 2026 -- IGT and Everi will present a combined portfolio of slot games, casino management systems and FinTech products at the 2026 Global Gaming Expo (G2E) in Las Vegas, running Sept. 28 through Oct. 1, at booth 4455.

New titles debut on RISE32 and RISE55 cabinets

IGT will launch Lightning Rails and Split 'N' Win Link Boost on its RISE32 cabinet, both offering player-selectable denomination configurations. The RISE55 cabinet will host premium evolutions Money Gong Divine and Tiger and Dragon Power Sphere, alongside Piggz Link base games Frankenswine and Prince of Porkness, and Triple Coin Link themes Grand Buddha and Grand Cat.

Mesquite, Texas – September 21, 2026 -- Ernest Health has secured development sites in six North Carolina markets for freestanding inpatient rehabilitation hospitals, marking Phase 1 of a statewide expansion program. The company controls parcels in Winston-Salem, Mooresville, Gastonia, Hickory, South Asheville/Arden and Goldsboro through development partner Summit Healthcare Group.

Six sites move from announcement to construction-ready status

Summit Healthcare Group, a Winston-Salem-based healthcare real estate firm founded in 2008 with more than 750,000 square feet of ground-up healthcare delivery experience, now holds control of all six parcels. The sites span the Piedmont Triad, the Lake Norman and Gaston County submarkets of Charlotte, the Catawba Valley, Western North Carolina and Eastern North Carolina. Each location was chosen for proximity to acute care referral sources, transportation access and local older-adult population density.

Jerusalem – September 21, 2026 -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has regained compliance with Nasdaq's $1.00 minimum bid price rule after its American Depositary Shares closed at or above that threshold for 19 consecutive business days, Nasdaq Listing Qualifications confirmed in a September 18, 2026 letter.

Nasdaq closes compliance matter after ADS price clears threshold for 19 sessions

The closing bid price of Scinai's ADSs met or exceeded $1.00 per share from August 21, 2026 through September 17, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq had first flagged the deficiency on March 12, 2026, after the ADSs failed to maintain the $1.00 minimum over the prior 30 consecutive business days.

CEO says resolution shifts focus to CDMO commercial execution

"Receiving Nasdaq's confirmation closes an important compliance matter for Scinai,

Bridgewater, N.J. – September 21, 2026 -- The U.S. Food and Drug Administration has accepted Insmed Incorporated's supplemental New Drug Application (sNDA) for full approval of ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease, granting Priority Review with a PDUFA target action date of January 28, 2027.

FDA sets January 28, 2027 decision date under Priority Review

The Priority Review designation applies to therapies that could offer significant improvement in safety or efficacy for serious conditions. Insmed said full approval would allow ARIKAYCE, administered via PARI Pharma's Lamira Nebulizer System, to reach patients earlier in their disease course, including newly diagnosed cases and those with recurrent infections.

Germantown, Md. – September 21, 2026 -- The U.S. Food and Drug Administration has granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, the technology underlying the company's first commercial product, PAPZIMEOS, approved in August 2025 for recurrent respiratory papillomatosis (RRP) in adults.

FDA designation opens accelerated pathway for future AdenoVerse cancer programs

The designation allows Precigen to leverage manufacturing and preclinical data generated for PAPZIMEOS to support future marketing applications for other AdenoVerse-based candidates, reducing duplicative development work. It also grants the company earlier and more frequent FDA engagement and allows regulators to consider prior manufacturing inspections when reviewing future applications.

Los Angeles – September 21, 2026 -- Fluxnium, Inc. has closed a $7 million seed round led by Congruent Ventures to commercialize technology that adsorbs uranium directly from seawater, targeting a domestic alternative to mined ore for nuclear fuel supply. Constellation Technology Ventures, the venture arm of Constellation (NASDAQ: CEG), and Active Impact Investments, Canada's largest climate tech seed fund, also participated in the round.

Seawater holds roughly 1,000 times more uranium than all identified land deposits combined

Fluxnium's proprietary high-surface-area fiber, developed in partnership with a U.S. national laboratory, passively captures dissolved uranium as seawater flows through it. The fiber deploys on longline systems in open water, the same passive infrastructure used in commercial seaweed and mussel farming, then is retrieved, processed and redeployed.

Dallas – September 21, 2026 -- enCore Energy Corp. (NASDAQ, TSXV: EU) has engaged North Star Investor Relations Inc. under a consulting agreement effective September 18, 2026, paying a monthly cash retainer of CAD $10,000 for shareholder outreach, capital markets intelligence and media coordination.

North Star retainer runs for one year with a 30-day termination clause

The initial term of the Consulting Agreement is one year, renewable by mutual agreement, and either party may terminate on 30 days' written notice. North Star is owned by Graham Farrell and operates from Toronto; the firm and its principals are at arm's length to enCore and held no company securities when the agreement was signed. The engagement remains subject to TSXV approval.

Johnston, Iowa and Ghent, Belgium – September 21, 2026 -- Vylor, the seed and genetics company set to spin off from Corteva on October 1, 2026, has partnered with Belgium's Rainbow Crops to develop climate-resilient corn traits using AI-driven multiplex gene editing.

Rainbow Crops' Trait Foundry platform edits hundreds of genes simultaneously

The collaboration will deploy Rainbow Crops' AI-supported Trait Foundry™ technology, which combines multiplex genome editing, precision breeding and automated phenotyping to accelerate development of corn hybrids resistant to heat, drought and flooding. Mat Muller, who will lead Vylor Edge, Vylor's investment arm, said the platform allows scientists to make hundreds of gene edits simultaneously while validating performance through phenotyping facilities and field trials.